Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®
← catalyst calendarNCT07070115 · readout in 1,960 d
Sponsored by Tela Bio Inc (industry) · TELA — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
173estimated
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-25 | actual | When the study began enrolling |
| Primary completion | 2031-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hiatal Hernia
Intervention
- Device: OviTex Reinforced Tissue Matrix
Primary outcome
what the primary-completion date above is the date OFHernia recurrence
measured At 24 months
Permalink · TELA's whole pipeline · Catalyst calendar · Every registered study · What changed